South East Asia Journal of Medical Sciences
Volume 7, Issue 3; 2023
pISSN: 2520-7342, eISSN: 2522-7165
Editorial

The Power of Computational Chemogenomics and In Silico Tools for Drug Discovery

Ambadasu Bharatha Lecturer in Pharmacology, Faculty of Medical Sciences, The University of the West Indies, Cave Hill, Barbados

*Kandamaran Krishnamurthy** Consultant Pediatric Intensive Care Unit Queen Elizabeth Hospital, Barbados.

**Corresponding Author*
kandamaran.krishnamurthy@cavehill.uwi.edu

Introduction

In recent years, pharmacological research and drug discovery have been significantly impacted by the development of computational chemogenomics and in silico tools. These powerful techniques are transforming the way scientists explore and design new therapeutic agents, allowing for faster, more efficient drug development.

Computational Chemogenomics

Traditionally, the drug development process relied significantly on experimental screening of huge chemical libraries, which was both time-consuming and costly. Computational chemogenomics takes a novel approach to this process by predicting how chemicals interact with specific target proteins using the large quantity of available biological data [1]. This data-driven strategy helps researchers to focus on the most promising medication ideas, lowering drug discovery time and the cost of the drug discovery process.

The development of machine learning algorithms that can effectively handle big datasets and accurately predict drug-target interactions is one of the most significant advances in computational chemogenomics [2]. These algorithms have been used successfully to find new therapeutic targets and drug candidates for a variety of diseases, including cancer and neurological disorders [3].

In Silico Tools

Modern drug development pipelines are unable to function without in silico techniques. Researchers can examine how potential drugs bind to their target proteins using these computational techniques that mimic molecular interactions.[4]. Scientists can anticipate the efficacy and safety of possible drug candidates by investigating these interactions at the molecular level before investing in costly and time-consuming experimental research [5].

In silico tools have also been effective in the optimisation of lead compounds. Using tools such as molecular docking and molecular dynamics simulations, researchers can evaluate various chemical alterations to improve the efficacy of potential drug candidates [6].

Challenges and Future Directions

Despite substantial advances in computational chemogenomics and in silico tools, some challenges remain. For example, the accuracy of these procedures is dependent on the quality and availability of biological data.[4]. Additionally, the complexity of biological systems can sometimes limit the predictive capabilities of these tools, requiring further experimental validation [7].

However, there is great potential for the future in the application of computational chemogenomics and in silico tools in pharmacological research and drug discovery. We should expect these methods to become more and more important in the creation of new and effective medications as our knowledge of biological systems advances and computational capabilities increase.

Benefits and Limitations

Integrating computational chemogenomics and in silico tools in pharmacological research has several notable benefits. As mentioned earlier, these techniques can significantly reduce the time and cost associated with drug discovery, enabling researchers to focus on the most promising drug candidates [8, 3]. Additionally, in silico methods can help minimise the use of animals in the early stages of drug development by providing a preliminary assessment of drug efficacy and safety [5].

However, there are also some limitations to these approaches. First, the accuracy of computational predictions heavily depends on the quality of available data [7]. Predictions made using incomplete or biased data sets may be incorrect, which could impede the drug discovery process. Additionally, while in-silico tools might provide insightful information about molecular interactions, they can not always accurately represent complex dynamics and interactions that occur in vivo [9]. Therefore, experimental validation is still important in the process of discovering new drugs.

Conclusion

It may be possible to completely change how drugs are developed by utilising computational chemogenomics and in silico tools in pharmacological research and drug discovery. By utilising the enormous amount of biological data that is already available and utilising the strength of machine learning algorithms, researchers can hasten drug discovery, reduce costs, and eventually provide patients with more effective medications. While problems exist, combining these methodologies with established experimental methods will continue to impact the future of drug discovery and pave the path for novel therapeutic treatments.

References

1. Bhargava H, Sharma A, Suravajhala P. Chemogenomic Approaches for Revealing Drug Target Interactions in Drug Discovery. Curr Genomics. 2021 Dec 30;22(5):328-338. doi: 10.2174/1389202922666210920125800. PMID: 35283667; PMCID: PMC8844939.
2. Wang Y, Zeng J. Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics. 2013 Jul 1;29(13):i126-34. doi: 10.1093/bioinformatics/btt234. PMID: 23812976; PMCID: PMC3694663.
3. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. Artif Intell Rev. 2022;55(3):1947-1999. doi: 10.1007/s10462-021-10058-4. Epub 2021 Aug 11. PMID: 34393317; PMCID: PMC8356896.
4. Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023 Apr;616(7958):673-685. doi: 10.1038/s41586-023-05905-z. Epub 2023 Apr 26. PMID: 37100941.
5. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol. 2007 Sep;152(1):21-37. doi: 10.1038/sj.bjp.0707306. Epub 2007 Jun 4. PMID: 17549046; PMCID: PMC1978280.
6. Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational/in silico methods in drug target and lead prediction. Brief Bioinform. 2020 Sep 25;21(5):1663-1675. doi: 10.1093/bib/bbz103. PMID: 31711157; PMCID: PMC7673338.
7. Henninger HB, Reese SP, Anderson AE, Weiss JA. Validation of computational models in biomechanics. Proc Inst Mech Eng H. 2010;224(7):801-12. doi: 10.1243/09544119JEIM649. PMID: 20839648; PMCID: PMC2941217.
8. Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational/in silico methods in drug target and lead prediction. Brief Bioinform. 2020 Sep 25;21(5):1663-1675. doi: 10.1093/bib/bbz103. PMID: 31711157; PMCID: PMC7673338.
9. Barh D, Chaitankar V, Yiannakopoulou EC, Salawu EO, Chowbina S, Ghosh P, Azevedo V. In Silico Models: From Simple Networks to Complex Diseases. Animal Biotechnology. 2014:385–404. doi: 10.1016/B978-0-12-416002-6.00021-3. Epub 2013 Nov 15. PMCID: PMC7149665.